Last Posted: Feb 13, 2020
- Major Strides in HER2 Blockade for Metastatic Breast Cancer
P Sharma, NEJM, February 12, 2020 - Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
S Modi et al, NEJM, February 12, 2020 - Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
Kurian Allison W et al. JAMA oncology 2020 Feb e196400 - Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
Kittaneh Muaiad et al. Clinical breast cancer 2020 Jan - Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup I M H et al. Acta oncologica (Stockholm, Sweden) 2018 Jan 57(1) 95-101 - Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test.
Shin Hee-Chul et al. Cancer research and treatment : official journal of Korean Cancer Association 2020 Feb - Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their Relatives.
Seven Memnun et al. Cancer nursing 2020 Jan - Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer.
Napoli Melissa et al. Journal of genetic counseling 2020 Feb - Gail Model Underestimates Breast Cancer Risk in Thai Population.
Sa-Nguanraksa Doonyapat et al. Asian Pacific journal of cancer prevention : APJCP 2019 20(8) 2385-2389 - Genetic testing in young women with breast cancer: results from a Web-based survey.
Ruddy K J et al. Annals of oncology : official journal of the European Society for Medical Oncology 2010 Apr 21(4) 741-7
.png)
No hay comentarios:
Publicar un comentario